Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Net Income · Q2 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q2 FY2026 net income of $4.45M (cash outflow) fell 90.4% year over year, ahead of the -388.6% change in trailing-twelve-month net income. Sequentially, it fell 80.7% from the prior quarter. Over 3 fiscal years it compounded at -1.9% a year.
Context
- Net income amounted to 4416.2% of revenue in FY2025.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$12.17M (-80.5%) for the fiscal year ending Sep 2026, a slowdown from the -17.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.45M-80.7% QoQ
- Last fiscal yearSep 2025
- -$62.42M-17.2% YoY
- LTMMar 2026
- -$60.96M-388.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -90.4% | -45.7% | +44.7 pp |
| 1 year | -17.2% | -80.5% | -63.3 pp |
| 3-year CAGR | -1.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (62.42M) USD
- Year-over-year change
- +17.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | (62.42M) | +17.2% |
| FY2024 | 2024-09-30 | (75.37M) | -27.8% |
| FY2023 | 2023-09-30 | (58.98M) | +10.7% |
| FY2022 | 2022-09-30 | (66.05M) | -24.2% |
| FY2021 | 2021-09-30 | (53.16M) | — |
Net Income vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 net income of $60.96M is the 3rd largest of the 9 companies compared; the peer median is $29.58M.
- Its year-over-year change of -388.6% is the lowest of 9, against a peer median of +7.2%.
- Net income amounts to 18297.5% of revenue for OTLK, versus a peer median of 532.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $28.76B | +254398.4% | +1562.8% | — |
| LTM Mar 2026 | $107.79M | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $60.96M | -388.6% | -1.9% | 18297.5% | |
| LTM Mar 2026 | $37.19M | -32.9% | -5.5% | — | |
| LTM Jun 2026 | $34.61M | -52.7% | +4.2% | 164.8% | |
| LTM Mar 2026 | $24.54M | +1.8% | -10.4% | 1070.2% | |
| LTM Mar 2026 | $19.52M | -51.9% | -20.5% | 59.6% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| LTM Mar 2026 | $12.72M | +12.6% | -31.8% | 899.5% | |
| Peer median (excluding OTLK) | $29.58M | +7.2% | -15.5% | 532.1% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| Deferred Income Tax | 498.49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.89M | 7.71M | 5.55M | 5.39M | 8.9M |
| Change in Working Capital | (7.08M) | (1.68M) | 4.75M | (3.02M) | 4.86M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (1.49M) |
| Inventory | 0 | 0 | 0 | 0 | (3.34M) |
| Accounts Payables | (198.47K) | 1.3M | 3.08M | 1.39M | 1.67M |
| Other Working Capital | (6.88M) | (2.98M) | 1.67M | (4.41M) | 8.02M |
| Other Non-Cash Items | 341.55K | 3.15M | 5.66M | 4.09M | 1.58T |
| Operating Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (3) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 6.31M | (2.32M) | 19.77M | (4.27K) | (3.04M) |
| Common Stock Issued | 46.3M | 62.31M | 30.02M | 60.33M | 48.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | (394.15K) | (823.89K) | 0 | 44.98T |
| Financing Cash Flow | 56.19M | 59.59M | 48.97M | 60.33M | 44.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.94M | 2.92M | 6M | (8.46M) | (6.84M) |
| Free Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.